NCT04593654

Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients

Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients - More Patients Included and 90-day Follow up

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 257 (actual)
• Sponsor: Karolinska Institutet · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The aim of the study is to associate dose of thromboprophylaxis with outcome in critically ill COVID-19 patients. This will be done by associating dose of thromboprophylaxis with 28-day mortality, survival outside ICU, thromboembolic event and bleeding complications.This was done in our earlier study for patients admitted in March and April (Clinicaltrials.gov NCT04412304 June 2 2020) but now we will include the patients admitted in May, June and half of July and we will ad the outcome of 90-day mortality.

Conditions

• Covid19
• Thromboembolism

Interventions

Type	Name	Description
DRUG	Dose of tinzaparin or dalteparin	The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU

Timeline

• Start date: 2020-03-01
• Primary completion: 2020-08-15
• Completion: 2020-10-15
• First posted: 2020-10-20
• Last updated: 2023-05-31

Locations

1 site across 1 country: Sweden